Inflammation is considered to be an important contributing factor of the pathophysiology of coronary heart disease (CHD), and the inflammatory cascade is important in the atherosclerotic process. Chronic inflammation plays asignificant role in the initiation and development of atherosclerosis. There are various inflammatory markers that have been suggestedand hence the measurement of inflammatory marker‟s serum level to predict cardiovascular events in the identified patients. In the recent year investigations have found an association between inflammatory markers and CHD. Among these biomarkers, C-reactive protein (CRP) has emerged as one of the most important novel inflammatory markers.Elevated baseline concentrations of hs-CRP are associated with the risk of atherosclerotic events in general populations and show a predictive value even in terms of secondary prevention. These markers have proven useful as prognostic indicators in acute coronary syndromes and in predicting future coronary events in apparently healthy population. In recent year, a lot of concerns have emerged about the experimental models used to study the role of CRP in atherosclerosis; moreover, the results of trials evaluating the clinical association between this molecules and outcome are still controversial. In this review, we discuss the evidence associating these inflammatory markers, especially CRP, with the mechanism of risk as well as the clinical utility of this marker.